Sugi Predict

Sugi Predict / Compounds / SCHEMBL18593158

SCHEMBL18593158

SCHEMBL18593158

CCOC(=O)[C@@H]1C[C@@H](O)C(=O)N1C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.38
▸ NFKB1 P19838 1/20 0.37
▸ NFKB2 Q00653 1/20 0.37
▸ RELA Q04206 1/20 0.37
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ TSHR P16473 1/20 0.36
▸ GLA P06280 1/20 0.35
▸ FKBP1A P62942 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ NR1H2 P55055 1/20 0.34
▸ POLB P06746 1/20 0.33
▸ KLK7 P49862 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18593159 0.86 MAPT (0.38) MAPTNFKB1NFKB2RELACHRM2
SCHEMBL15896630 0.86 MAPT (0.38) MAPTNFKB1NFKB2RELACHRM2
SCHEMBL25517002 0.86 MAPT (0.38) MAPTNFKB1NFKB2RELACHRM2
SCHEMBL12423750 0.86 MAPT (0.38) MAPTNFKB1NFKB2RELACHRM2
SCHEMBL8214876 0.86 MAPT (0.38) MAPTNFKB1NFKB2RELACHRM2
SCHEMBL30992286 0.86 MAPT (0.44) MAPTNFKB1NFKB2RELACHRM2
SCHEMBL19521085 0.85 CHRM2 (0.39) MAPTCHRM2CHRM1CHRM3ALDH1A1
SCHEMBL19521086 0.85 CHRM2 (0.39) MAPTCHRM2CHRM1CHRM3ALDH1A1
SCHEMBL19521084 0.85 CHRM2 (0.39) MAPTCHRM2CHRM1CHRM3ALDH1A1
SCHEMBL3192039 0.83 NFKB1 (0.38) MAPTNFKB1NFKB2RELACHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210047319-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-02-18 — — US disclosed
US-10023571-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2018-07-17 — — US disclosed
US-10023571-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2018-07-17 — — US disclosed
US-20170066763-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-09 — — US disclosed
US-20170066763-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-09 — — US disclosed
WO-2017040757-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2017-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066763-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 MAPT 1236/4885NFKB1 2358/4885NFKB2 1990/4885
US-10023571-B2 TYK2 inhibitors and uses thereof TYK2, JAK1, JAK2 MAPT 1228/4885NFKB1 2392/4885NFKB2 2191/4885
US-20210047319-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 MAPT 1236/4885NFKB1 2358/4885NFKB2 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.